EMA Authorised: Kayfanda (odevixibat sesquihydrate) — Ipsen Pharma

View source ↗

Summary

The EMA authorised Kayfanda (odevixibat sesquihydrate) for pruritus and Alagille syndrome, manufactured by Ipsen Pharma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alagille Syndrome
• Pruritus

Drugs mentioned

• Kayfanda (odevixibat sesquihydrate)

Snippet

Status: Authorised. Therapeutic area: Pruritus;Alagille Syndrome. MAH: Ipsen Pharma. Decision date: 07/05/2025